Regeneron Expects to Avoid New US Pharmaceutical Tariffs
Regeneron expects to avoid new tariffs by reaching a deal with the government to lower drug prices. The firm is the last of seventeen major drugmakers to sign.
Xurve View
Insights:
Xurve View
Regeneron Pharmaceuticals announced on Thursday its expectation to be excluded from a forthcoming list of pharmaceutical companies that may face new tariffs from the government of the United States. This follows reports that the administration is preparing to penalize drugmakers that have not yet reached agreements to guarantee lower prescription prices.
